WAM
CRXTW

Warberg Asset Management’s Clarus Therapeutics Holdings, Inc. Warrants CRXTW Stock Holding History

Warberg Asset Management’s Portfolio CRXTW Stock Details CRXTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-65,000
Closed -$10K – 289
2022
Q1 		$10K Buy
65,000
+32,498
+100% +$5.89K ﹤0.01% 207
2021
Q4 		$9K Sell
32,502
-107,338
-77% -$54.9K ﹤0.01% 194
2021
Q3 		$105K Buy
+139,840
New +$105K 0.02% 133

Other funds holding CRXTW

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Warberg Asset Management's CRXTW Position: Q2 2022 in Review

Warberg Asset Management sold out of Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) in Q2 2022, closing a stake of 65,000 shares — an estimated $10K sold.

Warberg Asset Management first reported a position in CRXTW in Q3 2021 and held it in 3 quarters. The position peaked at $105K in Q3 2021. 18 funds tracked by Wall St. Rank hold CRXTW as of Q2 2022.

  • Warberg Asset Management reported no remaining Clarus Therapeutics Holdings, Inc. Warrants position as of Q2 2022 after selling out during the quarter.
  • Warberg Asset Management sold 65,000 Clarus Therapeutics Holdings, Inc. Warrants shares in Q2 2022, an estimated $10K.
  • Warberg Asset Management first reported a position in Clarus Therapeutics Holdings, Inc. Warrants in Q3 2021 and held it in 3 quarters.
  • Warberg Asset Management's Clarus Therapeutics Holdings, Inc. Warrants position peaked at $105K in Q3 2021.
  • 18 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Warrants as of Q2 2022.

Based on Warberg Asset Management's 13F filing for Q2 2022, filed 11 Aug 2022.